Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
2026-02-17 12:58:58 ET
On February 13, 2026, First Turn Management disclosed a new position in Cogent Biosciences (NASDAQ:COGT) , acquiring 824,283 shares worth $29.28 million at quarter’s end.
According to a recent SEC filing dated February 13, 2026, First Turn Management disclosed a new purchase of 824,283 shares of Cogent Biosciences. The fund reported the new position at quarter end, with the value reflecting both the initial investment and any market price changes during the period.
Cogent Biosciences is a clinical-stage biotechnology company specializing in targeted therapies for genetically driven diseases. The company's strategy focuses on leveraging scientific expertise and strategic partnerships to advance innovative treatments addressing significant unmet medical needs. Cogent's competitive edge lies in its precision approach and commitment to developing selective inhibitors for challenging molecular targets.
NASDAQ: COGT
COGT Trading
-0.4% G/L:
$36.40 Last:
551,036 Volume:
$36.80 Open:
